Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Divisional Update Highlights Consistent Program and Product Progress Across the Board

  • MINDCURE plans to schedule a pre-IND meeting with the FDA for its Desire Project during Q1 2022 with a subsequent Phase 2 trial to begin Q3 2022
  • The company expects that the GLP supply of ibogaine will be available for distribution to research partners in Q2 2022
  • Information on MC-106 and MC-808, an expansion of MINDCURE’s drug pipeline, will be released during Q2 2022

As a member of the Digital Therapeutics Alliance, Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) delivers digital therapeutics (“DTx”) that are evidence-based interventions driven by high-quality software to prevent, manage, and treat medical disorders or diseases. DTx can be used independently or with other medications, devices, or therapies, to optimize outcomes and patient care. MINDCURE is a leader in advanced proprietary technology and research centered around psychedelics and is currently advancing multiple programs and products to this end. 

The attested progress and plans for the immediate future were detailed in an operational update regarding the strategic initiatives of the company’s operating segments – MINDCURE Research and MINDCURE Technology (https://ibn.fm/pjF4K).

MINDCURE Research’s update included updates on both The Desire Project and Ibogaine. The company has completed its draft research protocol for the use of MDMA and psychotherapy to treat female hypoactive desire disorder (The Desire Project) and expects a pre-IND meeting with the FDA in Q1 2022 and a subsequent Phase 2 trial to commence in Q3 2022.

Earlier in 2021, MINDCURE announced that it would begin chemical synthesis routes to produce fully synthetic ibogaine. In July 2021, MINDCURE applied for patents on two routes for full chemical synthesis and initiated the production of Good Laboratory Practice (“GLP”), leading to the production of Good Manufacturing Practice (“GMP”) ibogaine. The company expects to have a GLP supply available for its research partners in Q2 2022.

In addition to The Desire Project and its ibogaine efforts, MINDCURE is continuing to explore its options to expand its drug pipeline. There are two candidate selection programs currently underway for what is internally known as MC-106 and MC-808. More information will be released in Q2 2022.

MINDCURE Technology also released an update on its DTx technology, iSTRYM, and its release as a minimum viable product (“MVP”) into partner clinics across North America. Although North America is the largest market for DTx, the global market was valued at $3.4 billion in 2020 and is expected to grow at a CAGR of 31.4% to reach $13.1 billion by 2026 (https://ibn.fm/y2EVV). The market’s expansion can potentially bring multiple opportunities for growth for the company, given the iSTRYM’s capability to easily scale at a global level as a drug-agnostic digital tool and distribution platform.

MINDCURE’s unique and diversified approach works with multiple touchpoints, including technology, research, and drug supply and partnerships. The distribution component of its platform was kicked off recently, via the company’s partnership with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF), a biotech company with clinical operations researching, developing, and delivering psychedelic medicine to treat addiction. Under the agreement, MINDCURE will leverage iSTRYM to distribute Awakn’s ketamine-assisted psychotherapy for Alcohol Use Disorder in the United States and Canada.

For more information, visit the company’s website at www.MindCure.com.

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Archives

Select A Month

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050